全文获取类型
收费全文 | 2027篇 |
免费 | 159篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 90篇 |
妇产科学 | 27篇 |
基础医学 | 324篇 |
口腔科学 | 33篇 |
临床医学 | 176篇 |
内科学 | 449篇 |
皮肤病学 | 79篇 |
神经病学 | 95篇 |
特种医学 | 199篇 |
外国民族医学 | 1篇 |
外科学 | 191篇 |
综合类 | 67篇 |
一般理论 | 1篇 |
预防医学 | 173篇 |
眼科学 | 18篇 |
药学 | 137篇 |
中国医学 | 5篇 |
肿瘤学 | 111篇 |
出版年
2022年 | 16篇 |
2021年 | 36篇 |
2020年 | 28篇 |
2019年 | 42篇 |
2018年 | 51篇 |
2017年 | 38篇 |
2016年 | 41篇 |
2015年 | 46篇 |
2014年 | 57篇 |
2013年 | 87篇 |
2012年 | 89篇 |
2011年 | 89篇 |
2010年 | 76篇 |
2009年 | 100篇 |
2008年 | 87篇 |
2007年 | 79篇 |
2006年 | 64篇 |
2005年 | 87篇 |
2004年 | 57篇 |
2003年 | 50篇 |
2002年 | 52篇 |
2001年 | 48篇 |
2000年 | 42篇 |
1999年 | 45篇 |
1998年 | 46篇 |
1997年 | 45篇 |
1996年 | 45篇 |
1995年 | 43篇 |
1994年 | 29篇 |
1993年 | 29篇 |
1992年 | 28篇 |
1991年 | 28篇 |
1990年 | 24篇 |
1989年 | 47篇 |
1988年 | 39篇 |
1987年 | 30篇 |
1986年 | 35篇 |
1985年 | 24篇 |
1984年 | 30篇 |
1983年 | 29篇 |
1982年 | 29篇 |
1981年 | 20篇 |
1980年 | 26篇 |
1979年 | 16篇 |
1978年 | 21篇 |
1977年 | 9篇 |
1976年 | 13篇 |
1975年 | 14篇 |
1974年 | 14篇 |
1968年 | 9篇 |
排序方式: 共有2194条查询结果,搜索用时 15 毫秒
41.
WBG Macdonald AP Patrikeos RI Thompson BD Adler AA Van Der Schaaf 《Journal of Medical Imaging and Radiation Oncology》2005,49(1):32-38
The present study compared the accuracy of ventilation perfusion scintigraphy (VQS) and CT pulmonary angiography (CTPA) for the diagnosis of pulmonary embolism. This was a prospective observational study of 112 patients with suspected pulmonary embolism (PE) who could be studied with both investigations within 24 h. Results were compared to final diagnosis at completion of 6-month follow up, using receiver operating characteristic (ROC) analysis. Pulmonary embolism was diagnosed in 27 referred patients (24%). The sensitivity and specificity of VQS and CTPA were similar to that reported from the literature. A normal VQ scan had the highest negative predictive value (100%), while a high-probability VQ scan had the highest positive predictive value (92%). There was no overall difference (area under the ROC curve (AUC)) between VQS (AUC (95% CI) = 0.82 (0.75,0.89)) and CTPA (AUC = 0.88 (0.81,0.94)) for the diagnosis of PE. Among patients with abnormal chest X-rays, CTPA (AUC 0.90 (0.83,0.97)) appeared somewhat better than VQS (AUC 0.78 (0.68,0.88)) but this difference did not reach statistical significance. In this instance, CTPA is at least as accurate as VQS and may provide an opportunity to make alternative diagnoses. 相似文献
42.
43.
Impact of induction treatment before autologous stem cell transplantation on long‐term outcome in patients with newly diagnosed multiple myeloma
下载免费PDF全文
![点击此处可从《European journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
44.
45.
46.
47.
Fabián Matías Caro María Laura Alberti Federico Campins Juan Ignacio Enghelmayer Martín Eduardo Fernández Diana Lancellotti Tulio Papucci Javier Adrián Sebastiani Francisco Paulin 《Archivos de bronconeumologia》2019,55(2):75-80
Introduction
Pirfenidone was the first antifibrotic drug approved in Argentina for idiopathic pulmonary fibrosis (IPF). Outcomes in real life may differ from the results of clinical trials. The primary endpoint was to study the tolerance of pirfenidone in real life. Secondary endpoints were to analyze effectiveness and reasons for discontinuation.Materials and methods
Retrospective observational study conducted in four specialized centers in Argentina. We analyzed the medical records of patients with IPF who received pirfenidone between June 2013 and September 2016. Adverse events (AE) and the variables that could influence these results were analyzed. Forced vital capacity (FVC%) parameters were also compared between the pre-pirfenidone and post-pirfenidone periods.Results
Fifty patients were included, 38 (76%) men, with mean age (SD) 67.8 (8.36) years. Mean (SD) exposure to pirfenidone was 645.68 (428.19) days, with a mean daily dose (SD) of 2064.56 mg (301.49). Nineteen AEs in 15 patients (30%) were reported: nausea (14%), asthenia (10%) and skin rash (8%). A total of 18 patients (36%) interrupted treatment, only 1 definitively. The most frequent reason for discontinuation was failure of suppliers to provide the drug (9 subjects; 18%). We compared the evolution of FVC% between the pre-pirfenidone and post-pirfenidone periods, and found a mean (SD) FVC% decline of 4.03% (7.63) pre-pirfenidone and 2.64% (7.1) post-pirfenidone (P=.534).Conclusions
In our study, pirfenidone was well tolerated and associated with a reduction in FVC decline, although without reaching statistical significance. 相似文献48.
49.
50.